ADR News Bulletin 2024 April (Volume 26 Number 1)
29 April 2024
Audiences
Healthcare professional
Industry member
Product-type
Therapeutic Products
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Pseudoephedrine and the rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)
Analysis of adverse event reports for year 2023
AE Case in Focus 1: Test Yourself - What could have caused the blistering rash in this patient?
AE Case in Focus 2: Test Yourself - What could have caused the respiratory failure in this patient?
Click on the link below to download the issue in pdf:
ADR_News_April2024_Vol26_No1 [PDF, 2407 KB] (opens in new tab)
New drugs approved in 2023:
Healthcare professionals are encouraged to report all serious and non-serious suspected adverse drug reactions (ADRs) with the use of new drugs. Your active participation in the ADR monitoring programme will provide valuable support to the post-marketing surveillance on drug safety.
Click on the link below to download the issue in pdf:
New Drugs Approved for 2023 [PDF, 715 KB] (opens in new tab)
